These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 8424752)

  • 1. Synthesis of antimony complexes of yeast mannan and mannan derivatives and their effect on Leishmania-infected macrophages.
    Cantos G; Barbieri CL; Iacomini M; Gorin PA; Travassos LR
    Biochem J; 1993 Jan; 289 ( Pt 1)(Pt 1):155-60. PubMed ID: 8424752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
    Dzamitika SA; Falcão CA; de Oliveira FB; Marbeuf C; Garnier-Suillerot A; Demicheli C; Rossi-Bergmann B; Frézard F
    Chem Biol Interact; 2006 Apr; 160(3):217-24. PubMed ID: 16524568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine.
    Tempone AG; Perez D; Rath S; Vilarinho AL; Mortara RA; de Andrade HF
    J Antimicrob Chemother; 2004 Jul; 54(1):60-8. PubMed ID: 15163652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
    Carrió J; Portús M
    BMC Pharmacol; 2002 May; 2():11. PubMed ID: 12019027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.
    Roberts WL; Berman JD; Rainey PM
    Antimicrob Agents Chemother; 1995 Jun; 39(6):1234-9. PubMed ID: 7574507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoscaled hydrated antimony (V) oxide as a new approach to first-line antileishmanial drugs.
    Franco AM; Grafova I; Soares FV; Gentile G; Wyrepkowski CD; Bolson MA; Sargentini É; Carfagna C; Leskelä M; Grafov A
    Int J Nanomedicine; 2016; 11():6771-6780. PubMed ID: 28008252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.
    Ephros M; Bitnun A; Shaked P; Waldman E; Zilberstein D
    Antimicrob Agents Chemother; 1999 Feb; 43(2):278-82. PubMed ID: 9925518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
    Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG
    J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity.
    Borborema SE; Osso Junior JA; Andrade Junior HF; Nascimento Nd
    Rev Soc Bras Med Trop; 2016 Apr; 49(2):196-203. PubMed ID: 27192589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia.
    Fernández OL; Diaz-Toro Y; Ovalle C; Valderrama L; Muvdi S; Rodríguez I; Gomez MA; Saravia NG
    PLoS Negl Trop Dis; 2014 May; 8(5):e2871. PubMed ID: 24853871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimony determination in tissues and serum of hamsters infected with Leishmania garnhami and treated with meglumine antimoniate.
    Lugo de Yarbuh A; Añez N; Petit de Peña Y; Burguera JL; Burguera M
    Ann Trop Med Parasitol; 1994 Feb; 88(1):37-41. PubMed ID: 8192513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis.
    Lanza JS; Fernandes FR; Corrêa-Júnior JD; Vilela JM; Magalhães-Paniago R; Ferreira LA; Andrade MS; Demicheli C; Melo MN; Frézard F
    Int J Nanomedicine; 2016; 11():2305-18. PubMed ID: 27307731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
    Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
    J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis.
    Roberts WL; Hariprashad J; Rainey PM; Murray HW
    Am J Trop Med Hyg; 1996 Oct; 55(4):444-6. PubMed ID: 8916804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
    Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
    J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental chemotherapy in cutaneous leishmaniasis. III. Effect of glucantime and humatin (P&D) on Leishmania garnhami and Leishmania braziliensis in hamsters].
    Rezzano S; Armas JA; Moreno G; Scorza JV
    Acta Cient Venez; 1984; 35(5-6):394-403. PubMed ID: 6537698
    [No Abstract]   [Full Text] [Related]  

  • 17. Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice.
    Borborema SE; Osso JA; Andrade HF; Nascimento Nd
    Mem Inst Oswaldo Cruz; 2013 Aug; 108(5):623-30. PubMed ID: 23903979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of meglumine antimoniate, a pentavalent antimonial drug, on Leishmania promastigotes.
    Moreira ES; Petrillo-Peixoto ML
    Braz J Med Biol Res; 1991; 24(5):459-69. PubMed ID: 1823261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
    Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
    Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and characterization of bismuth(III) and antimony(V) porphyrins: high antileishmanial activity against antimony-resistant parasite.
    Gomes ML; DeFreitas-Silva G; dos Reis PG; Melo MN; Frézard F; Demicheli C; Idemori YM
    J Biol Inorg Chem; 2015 Jul; 20(5):771-9. PubMed ID: 25929728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.